LCTX Stock Lineage Cell Therapeutics (LCTX, $0.93) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 6, 2024

GET DAILY SIGNALS

Get AI intraday signals

LCTX - Lineage Cell Therapeutics

MACD signal

View

Odds of UP Trend

Price: $0.925

Daily change: +$0.0805 (+9.53%)

Daily volume: 996.8K

Capitalization: $174.7M

Industry: Biotechnology

Momentum Indicator for LCTX turns positive, indicating new upward trend

LCTX saw its Momentum Indicator move above the 0 level on November 06, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 114 similar instances where the indicator turned positive. In of the 114 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on November 06, 2024. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

LCTX moved above its 50-day moving average on November 06, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 154 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for LCTX crossed bearishly below the 50-day moving average on October 11, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LCTX broke above its upper Bollinger Band on November 06, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.623) is normal, around the industry mean (13.983). P/E Ratio (0.000) is within average values for comparable stocks, (100.519). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.946). LCTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (27.701) is also within normal values, averaging (223.316).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.